306 related articles for article (PubMed ID: 30040957)
1. Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications.
Kim J; Zhang K; Cai W; YorkWilliams S; Ua Cruadhlaoich MAI; Llanes S; Menon V; Poston KL
Neuropsychologia; 2018 Oct; 119():24-33. PubMed ID: 30040957
[TBL] [Abstract][Full Text] [Related]
2. Compensatory neural mechanisms in cognitively unimpaired Parkinson disease.
Poston KL; YorkWilliams S; Zhang K; Cai W; Everling D; Tayim FM; Llanes S; Menon V
Ann Neurol; 2016 Mar; 79(3):448-63. PubMed ID: 26696272
[TBL] [Abstract][Full Text] [Related]
3. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
[TBL] [Abstract][Full Text] [Related]
4. Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson's disease.
Schönberger AR; Hagelweide K; Pelzer EA; Fink GR; Schubotz RI
Neuropsychologia; 2015 Oct; 77():409-20. PubMed ID: 26382750
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
6. Cognitive performance in mid-stage Parkinson's disease: functional connectivity under chronic antiparkinson treatment.
Vancea R; Simonyan K; Petracca M; Brys M; Di Rocco A; Ghilardi MF; Inglese M
Brain Imaging Behav; 2019 Feb; 13(1):200-209. PubMed ID: 28942477
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
[TBL] [Abstract][Full Text] [Related]
8. Dopamine modulates striatal response to reward and punishment in patients with Parkinson's disease: a pharmacological challenge fMRI study.
Argyelan M; Herzallah M; Sako W; DeLucia I; Sarpal D; Vo A; Fitzpatrick T; Moustafa AA; Eidelberg D; Gluck M
Neuroreport; 2018 May; 29(7):532-540. PubMed ID: 29432300
[TBL] [Abstract][Full Text] [Related]
9. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
10. Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions.
Huang YT; Georgiev D; Foltynie T; Limousin P; Speekenbrink M; Jahanshahi M
Neuropsychologia; 2015 Aug; 75():577-87. PubMed ID: 26184442
[TBL] [Abstract][Full Text] [Related]
11. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
[TBL] [Abstract][Full Text] [Related]
12. Levodopa and the feedback process on set-shifting in Parkinson's disease.
Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
[TBL] [Abstract][Full Text] [Related]
13. It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
Straulino E; Scaravilli T; Bulgheroni M; D'Amico E; Castiello U
Neuropsychologia; 2016 Dec; 93(Pt A):106-115. PubMed ID: 27756693
[TBL] [Abstract][Full Text] [Related]
14. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease.
Wylie SA; van Wouwe NC; Godfrey SG; Bissett PG; Logan GD; Kanoff KE; Claassen DO; Neimat JS; van den Wildenberg WPM
Neuropsychologia; 2018 Jan; 109():262-269. PubMed ID: 29269306
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients.
De Gennaro L; Lanteri O; Piras F; Scarpelli S; Assogna F; Ferrara M; Caltagirone C; Spalletta G
Hum Brain Mapp; 2016 Mar; 37(3):1136-47. PubMed ID: 26704150
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
[TBL] [Abstract][Full Text] [Related]
18. Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients.
Kübler D; Schroll H; Buchert R; Kühn AA
J Neural Transm (Vienna); 2017 Sep; 124(9):1073-1081. PubMed ID: 28643101
[TBL] [Abstract][Full Text] [Related]
19. Dopamine and the regulation of cognition and attention.
Nieoullon A
Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
